AACR 2019 Abstract #2327
Key Messages:
- We demonstrate viral transfer feasibility in a point of care (POC) platform using an engineered lentiviral vector retargeted to CD3, which efficiently transduces freshly isolated resting human PBMCs in four hours
- POC modified cells successfully engraft and expand in vivo upon IV administration in mice
- The entire process of PBMCs isolation, genetic modification and dosing can be completed in less than twelve hours, vein to vein
- Altogether, this platform represents a significant step forward in advancing the development of CAR-T therapies with POC potentially expanding patient accessibility and deployment
